EN
DE 
NL 
FR 
ES 
IT 
CS 
PL CONDITION
PTSD is a widely cited reason for cannabis use, but the evidence is still thin. Many people with post-traumatic stress disorder report using cannabis, and there is real scientific interest, but high-quality trial evidence remains limited and inconclusive.
What the research says
The National Academies 2017 report found insufficient evidence to support or refute cannabis as an effective PTSD treatment. Some small studies and observational data suggest possible benefit for symptoms like nightmares (with nabilone) and sleep, but controlled trials are few and results are mixed.
A cautious picture
Interest is high and research is ongoing, but the current state of evidence does not support strong claims. There is also concern that heavy cannabis use can complicate PTSD and co-occurring conditions.
At a glance
What to be careful about
PTSD is a serious condition with effective evidence-based treatments. Cannabis is not an established treatment, and anyone struggling should seek professional mental-health support.
Continue exploring
Neuroimaging and randomized clinical trials in Molecular Psychiatry (Neumeister et al., 2013, PMID 23670490), Psychoneuroendocrinology (Jetly et al., 2015, PMID 25467221), and PLOS ONE (Bonn-Miller et al., 2021, PMID 33730032) examine how cannabinoids interact with amygdala-prefrontal fear-extinction circuits and trauma-related sleep disturbances. While synthetic CB1 agonists (nabilone) reduced trauma nightmares in crossover trials, randomized trials of whole-plant cannabis show mixed efficacy compared with placebo and highlight the need for careful dosing alongside sleep management.
Frequently Asked Questions
How is the endocannabinoid system altered in PTSD neuroimaging studies?
PET neuroimaging by Neumeister et al. (2013, PMID 23670490) found reduced circulating anandamide (AEA) and compensatory upregulation of amygdala-hippocampal CB1 receptors in individuals with PTSD.
What did randomized trials show regarding cannabinoids and PTSD nightmares?
In a double-blind placebo-controlled crossover trial in military personnel (Jetly et al., 2015, PMID 25467221), the synthetic CB1 agonist nabilone significantly reduced trauma-related nightmare frequency and intensity.
Did whole-plant cannabis outperform placebo in randomized PTSD trials?
In the first randomized placebo-controlled trial of smoked cannabis chemotypes in 80 veterans with PTSD (Bonn-Miller et al., 2021, PMID 33730032), all groups improved over 3 weeks, with no statistically significant difference between active chemotypes and placebo.
Sources & Psychiatric References
- Neumeister, A., Normandin, M. D., Pietrzak, R. H., et al. (2013). "Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study." Molecular Psychiatry, 18(9), 1034-1040. PubMed PMID 23670490.
- Jetly, R., Heber, A., Fraser, G., & Boisvert, D. (2015). "The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study." Psychoneuroendocrinology, 51, 585-588. PubMed PMID 25467221.
- Bonn-Miller, M. O., Sisley, S., Riggs, P., et al. (2021). "The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial." PLOS ONE, 16(3), e0246990. PubMed PMID 33730032.
English